Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
P7C3-S243 is a neuroprotective small molecule from the aminopropyl carbazole class, designed as a more drug-like, potent, and non-toxic derivative of the original P7C3 compound, lacking the aniline ring present in some earlier analogs. It acts by blocking neuronal apoptosis, thereby promoting neuronal survival, primarily through enhancing nicotinamide adenine dinucleotide (NAD) flux via activation of nicotinamide phosphoribosyltransferase. P7C3-S243 is orally bioavailable, metabolically stable, brain-penetrant, and effective in multiple preclinical animal models of neurodegenerative diseases—especially Alzheimer's disease, Parkinson's disease, and traumatic brain injury. It preserves axonal integrity, blocks neurodegeneration, and mitigates cognitive decline, with demonstrated efficacy and safety in both mice and rats[1][2][4][5][6][7][8][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on P7C3-S243.